Login to Your Account

Financings Roundup

Juventas Preps for Phase II Studies with $22M Series B

By Catherine Shaffer
Staff Writer

Tuesday, July 17, 2012
Juventas Therapeutics Inc., of Cleveland, is funded through the end Phase II trials for its biologic product, JVS-100, now that it has closed a $22.2 million Series B financing round co-led by Triathlon Medical Venture Partners and New Science Ventures.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription